Overview

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of the matrix fentanyl patch ZR-02-01 in providing relief of non-malignant chronic pain.
Phase:
Phase 3
Details
Lead Sponsor:
ZARS Pharma Inc.
Treatments:
Fentanyl